Cingulate Inc. — CTx-1301 (fixed dose, pediatric study) · ADHD.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/16/25) through T+5. Run-up high $11.66 on 3/19/26, low $3.6 on 6/1/26 (T-120 to T-1). FDA decision 6/2/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-02
OutcomeCRL
Drug / candidateCTx-1301 (fixed dose, pediatric study)